← Back to Search

Live Biotherapeutic Product

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Phase 1 & 2
Waitlist Available
Led By Shubham Pant, MD
Research Sponsored by 4D pharma plc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 of cycle 1 and cycle 2, time of treatment discontinuation up to a maximum of 35 treatment cycles (one cycle = 21 days), and 30 day follow up
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a combination of MRx0518 capsules and pembrolizumab infusions in patients with certain types of solid tumors. The goal is to enhance the body's natural defenses to better fight off cancer cells.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Melanoma
  • Solid Tumors
  • Kidney Cancer
  • Cancer
  • Bladder Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 of cycle 1 and cycle 2, time of treatment discontinuation up to a maximum of 35 treatment cycles (one cycle = 21 days), and 30 day follow up
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 of cycle 1 and cycle 2, time of treatment discontinuation up to a maximum of 35 treatment cycles (one cycle = 21 days), and 30 day follow up for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Part A: To assess the safety and tolerability of MRx0518 in combination with pembrolizumab through the collection of adverse events
Part B: To assess safety and tolerability of MRx0518 in combination with pembrolizumab through the collection of adverse events
Part B: To assess the clinical benefit of MRx0518 in combination with pembrolizumab
Secondary study objectives
Antitumour effect
Other study objectives
Biomarkers of treatment effect - blood
Biomarkers of treatment effect - tumour
Microbiota and metabolome
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: MRx0518 with pembrolizumabExperimental Treatment2 Interventions
Subjects will receive IV infusion of pembrolizumab once every 3 weeks until disease progression, unacceptable AEs or withdrawal of consent up to a maximum of 35 cycles (approx. 2 years). Starting on the day of first pembrolizumab dose, subjects will take one capsule of MR0518 twice daily until the end of the treatment period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
2019
Completed Early Phase 1
~10

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme LLCIndustry Sponsor
4,031 Previous Clinical Trials
5,189,713 Total Patients Enrolled
4D pharma plcLead Sponsor
8 Previous Clinical Trials
551 Total Patients Enrolled
Shubham Pant, MDPrincipal InvestigatorM.D. Anderson Cancer Center
4 Previous Clinical Trials
152 Total Patients Enrolled
~9 spots leftby Dec 2025